116 related articles for article (PubMed ID: 3810518)
1. [Seventh French Drug Surveillance Seminar. Caen, 21-22 November 1985].
Therapie; 1986; 41(5):323-84. PubMed ID: 3810518
[No Abstract] [Full Text] [Related]
2. [6th French seminar on drug surveillance. Clermont-Ferrand, 22-23 November 1984].
Therapie; 1985; 40(5):287-376. PubMed ID: 4095682
[No Abstract] [Full Text] [Related]
3. [Eighth French Drug Surveillance Seminar. Paris, 23-24 October 1986].
Therapie; 1987; 42(4):331-410. PubMed ID: 3686465
[No Abstract] [Full Text] [Related]
4. [Computerized detection of new adverse effects in drug surveillance. A proposal for the periodic use of the French data bank].
Pham E; Ventre JJ; Saddier P; Descotes J; Evreux JC
Therapie; 1988 May; 43(3):235-7. PubMed ID: 3420571
[No Abstract] [Full Text] [Related]
5. Measuring adverse drug reactions in a postmarketing surveillance system.
Fisher S; Bryant SG; Kluge RM
Psychopharmacol Bull; 1986; 22(1):272-7. PubMed ID: 3726073
[No Abstract] [Full Text] [Related]
6. Statewide test of a new postmarketing drug surveillance system.
Fisher S; Bryant SG; Solovitz BL; Kluge RM
Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262
[No Abstract] [Full Text] [Related]
7. Monitoring adverse drug reactions in the postmarketing phase.
Hoigné R; Hottinger S
Pharm Acta Helv; 1988; 63(1):2-12. PubMed ID: 3283774
[No Abstract] [Full Text] [Related]
8. [Is imputation in drug surveillance reliable?].
Girard M
Therapie; 1984; 39(3):291-6. PubMed ID: 6463954
[No Abstract] [Full Text] [Related]
9. Adverse drug reactions.
Turner P
Hum Toxicol; 1986 May; 5(3):161-2. PubMed ID: 3710492
[No Abstract] [Full Text] [Related]
10. [Drug surveillance as seen by the general practitioner. Apropos of a survey of 4175 physicians].
Begaud B; Haramburu F; Péré JC; Delmas N; Lorson B; Albin H
Therapie; 1984; 39(5):453-7. PubMed ID: 6506000
[No Abstract] [Full Text] [Related]
11. Possible strategies for early recognition of potential drug safety problems.
Venulet J
Adverse Drug React Acute Poisoning Rev; 1988; 7(1):39-47. PubMed ID: 3389236
[No Abstract] [Full Text] [Related]
12. [Necessity and difficulties of quantitative drug monitoring].
Lagier G; Dally S; Vincens M; Castot A
Therapie; 1983; 38(3):319-23. PubMed ID: 6612668
[No Abstract] [Full Text] [Related]
13. [Drug by drug imputation of adverse effects in drug monitoring. Attempted comparison of different methods].
Lagier G; Vincens M; Lefebure B; Frelon JH
Therapie; 1983; 38(3):295-302. PubMed ID: 6612666
[No Abstract] [Full Text] [Related]
14. [Chemical surveillance in the industrial environment].
Conso F
Rev Prat; 1987 Apr; 37(23):1321-5. PubMed ID: 3602879
[No Abstract] [Full Text] [Related]
15. [Imputability in drug monitoring. Principles of the balanced drug reaction assessment method and principal errors to avoid].
Lagier G; Vincens M; Castot A
Therapie; 1983; 38(3):303-18. PubMed ID: 6612667
[No Abstract] [Full Text] [Related]
16. Critical reflection on the collection and evaluation of adverse drug reaction data.
Venulet J
Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S48-53. PubMed ID: 3842691
[No Abstract] [Full Text] [Related]
17. [Comparative organization of drug monitoring in France and 7 European countries].
Vaissere J; de Cremiers F; Auriche M; Juillet Y
Therapie; 1986; 41(5):369-74. PubMed ID: 3810527
[No Abstract] [Full Text] [Related]
18. [Drug monitoring].
Royer RJ
Bull Soc Ophtalmol Fr; 1985 Nov; Spec No():11-30. PubMed ID: 4064240
[No Abstract] [Full Text] [Related]
19. Rhode Island physicians' recognition and reporting of adverse drug reactions.
Scott HD; Rosenbaum SE; Waters WJ; Colt AM; Andrews LG; Juergens JP; Faich GA
R I Med J (1976); 1987 Jul; 70(7):311-6. PubMed ID: 3476980
[No Abstract] [Full Text] [Related]
20. [Post-marketing surveillance of drugs: epidemiologic approach].
Stanulović M; Jakovljević V; Sabo A
Med Pregl; 1987; 40(11-12):573-7. PubMed ID: 3331415
[No Abstract] [Full Text] [Related]
[Next] [New Search]
